Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20241628 | 0.81 | TDO2 (0.33) | TDO2ALDH1A1TDP1HTT | |
| SCHEMBL13662722 | 0.81 | ELANE (0.38) | TDO2NOS3NOS2ALDH1A1TDP1 | |
| SCHEMBL20242026 | 0.80 | MAP4K4 (0.34) | NOS3NOS2PIK3CB | |
| SCHEMBL20249755 | 0.78 | NOS3 (0.39) | NOS3NOS2PIK3CB | |
| SCHEMBL20249908 | 0.76 | CA1 (0.30) | — | |
| SCHEMBL13662724 | 0.76 | NOTUM (0.47) | ALDH1A1TDP1HTT | |
| SCHEMBL28042403 | 0.74 | POLB (0.44) | NOS3NOS2ALDH1A1TDP1 | |
| SCHEMBL20390956 | 0.74 | — | — | |
| SCHEMBL20242125 | 0.74 | POLB (0.50) | — | |
| SCHEMBL13623576 | 0.74 | PDE10A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| WO-2018107056-A1 | 1,3-SUBSTITUED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACIC LEVELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | HSD17B4, CPT1A, ADH1A | TDO2 4274/4885NOS3 1009/4885NOS2 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.